Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CITIUS ONCOLOGY, INC.CTOR · Entity 6935 | Director | September 19, 2025 | December 22, 2025 |
| Citius Pharmaceuticals, Inc.CTXR · Entity 7778 | Director | November 07, 2024 | November 12, 2024 |
| DarioHealth Corp.DRIO · Entity 7024 | Director | September 24, 2026 | September 28, 2026 |
| FC Global Realty IncFCRE · Entity 169560 | Director | December 22, 2017 | December 28, 2017 |
| Lucid Diagnostics Inc.LUCD · Entity 6375 | Chief Financial Officer | February 20, 2026 | February 24, 2026 |
| PAVmed Inc.PAVM · Entity 7317 | President and CFO | April 02, 2026 | April 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CITIUS ONCOLOGY, INC.
Report date September 19, 2025 · Filed December 22, 2025 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 300,000 |
Reported balance
After 2025-09-19 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2025-09-19 · Grant · Acquired 300,000 · Balance 300,000 F1: Represents restricted stock units granted on September 19, 2025. The shares underlying the restricted stock units will vest in full on the third anniversary of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units granted on September 19, 2025. The shares underlying the restricted stock units will vest in full on the third anniversary of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date.
Citius Pharmaceuticals, Inc.
Report date November 07, 2024 · Filed November 12, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Purchase Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $0.38 · Expires 2034-11-07 | Direct | 125,000 |
Reported balance
After 2024-11-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-11-07 · Grant · Acquired 125,000 · Balance 125,000 F1: The options were granted on November 7, 2024. The options will vest 100% on the one-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of the vesting date. |
| Stock Option (Right to Purchase Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $0.70 · Expires 2033-10-10 | Direct | 75,000 |
Reported balance
Holding disclosure · report date 2024-11-07 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 75,000 F2: The options are vested in full and exercisable immediately. |
| Stock Option (Right to Purchase Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $1.42 · Expires 2033-02-07 | Direct | 75,000 |
Reported balance
Holding disclosure · report date 2024-11-07 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 75,000 F2: The options are vested in full and exercisable immediately. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted on November 7, 2024. The options will vest 100% on the one-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of the vesting date.
F2: The options are vested in full and exercisable immediately.
DarioHealth Corp.
Report date September 24, 2026 · Filed September 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 88,737 |
Reported balance
After 2026-09-24 transaction · row 1
1 source rowRow 1 · 2026-09-24 · Grant · Acquired 61,000 · Balance 88,737 F1: The restricted share award shall vest on the second anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted share award shall vest on the second anniversary of the grant date.
FC Global Realty Inc
Report date December 22, 2017 · Filed December 28, 2017 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| FC Global Common StockSEC Table I · non-derivative | Direct | 1,029,238 |
Reported balance
After 2017-12-22 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2017-12-22 · Other · Acquired 977,960 · Balance 1,029,238 F1: The transactions reported on this Form 4 were effected pursuant to a Convertible Payout Note dated May 17, 2017 and the Stock Grant Agreement dated December 22, 2017. F2: The price reported in Column 4 was set by the terms of the Convertible Payout Note dated May 17, 2017 and the Stock Grant Agreement dated December 22, 2017. F3: The total shares reflected in Column 5 includes the shares granted under the Convertible Payout Note dated May 17, 2017 and the Stock Grant Agreement dated December 22, 2017 as well as the shares previously held by Mr. McGrath after adjustment for a 1-for-5 reverse stock split in September 2016. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported on this Form 4 were effected pursuant to a Convertible Payout Note dated May 17, 2017 and the Stock Grant Agreement dated December 22, 2017.
F2: The price reported in Column 4 was set by the terms of the Convertible Payout Note dated May 17, 2017 and the Stock Grant Agreement dated December 22, 2017.
F3: The total shares reflected in Column 5 includes the shares granted under the Convertible Payout Note dated May 17, 2017 and the Stock Grant Agreement dated December 22, 2017 as well as the shares previously held by Mr. McGrath after adjustment for a 1-for-5 reverse stock split in September 2016.
Lucid Diagnostics Inc.
Report date February 20, 2026 · Filed February 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 1,813,569 |
Reported balance
After 2026-02-20 transaction · row 1
1 source rowRow 1 · 2026-02-20 · Grant · Acquired 470,000 · Balance 1,813,569 F1: Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed.
PAVmed Inc.
Report date April 02, 2026 · Filed April 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 186,695 |
Reported balance
After 2026-04-02 transaction · row 1
1 source rowRow 1 · 2026-04-02 · Grant · Acquired 180,000 · Balance 186,695 F1: Represents restricted stock granted to the reporting person under the Issuer's Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock granted to the reporting person under the Issuer's Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 24, 2026 Filed Sep 28, 2026 20:06 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock | 61,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-111350 · tm2626098-3_4seq1.xml · nonDerivative · entry 1 MCGRATH DENNIS M · CIK 0001269340 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,737 F1 · date: The restricted share award shall vest on the second anniversary of the grant date. Read SEC document |
| April 02, 2026 Filed Apr 3, 2026 20:51 UTC | PAVmed Inc. PAVM · Entity 7317 | GrantCommon stock | 180,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001094891-26-000157 · form4.xml · nonDerivative · entry 1 MCGRATH DENNIS M · CIK 0001269340 · President and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 186,695 F1 · shares: Represents restricted stock granted to the reporting person under the Issuer's Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed. Read SEC document |
| February 20, 2026 Filed Feb 24, 2026 23:30 UTC | Lucid Diagnostics Inc. LUCD · Entity 6375 | GrantCommon stock | 470,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001094891-26-000062 · form4.xml · nonDerivative · entry 1 MCGRATH DENNIS M · CIK 0001269340 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,813,569 F1 · shares: Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed. Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 20:12 UTC | PAVmed Inc. PAVM · Entity 7317 | GrantCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001094891-25-000040 · form4.xml · nonDerivative · entry 1 MCGRATH DENNIS M · CIK 0001269340 · President and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,834 F1 · shares: Represents restricted stock granted to the reporting person under the issuer's Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan with a single vesting date of May 20, 2028. Such restricted stock is subject to forfeiture if the requisite service period is not completed. F1 · price: Represents restricted stock granted to the reporting person under the issuer's Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan with a single vesting date of May 20, 2028. Such restricted stock is subject to forfeiture if the requisite service period is not completed. Read SEC document |
| September 19, 2025 Filed Sep 23, 2025 20:10 UTC | CITIUS ONCOLOGY, INC. CTOR · Entity 6935 | GrantCommon Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-090612 · ownership.xml · nonDerivative · entry 1 MCGRATH DENNIS M · CIK 0001269340 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 F1 · shares: Represents restricted stock awards granted on September 19, 2025. The shares will vest in three substantially equal installments on the first, second and third anniversaries of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date. Read SEC document |
| September 19, 2025 Filed Dec 1, 2025 21:10 UTC Amendment | CITIUS ONCOLOGY, INC. CTOR · Entity 6935 | GrantCommon Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-116679 · ownership.xml · nonDerivative · entry 1 MCGRATH DENNIS M · CIK 0001269340 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 F1 · shares: Represents restricted stock awards granted on September 19, 2025. The shares will vest in full on the third anniversary of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date. Read SEC document |
| September 19, 2025 Filed Dec 22, 2025 21:10 UTC Amendment | CITIUS ONCOLOGY, INC. CTOR · Entity 6935 | GrantCommon Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-124531 · ownership.xml · nonDerivative · entry 1 MCGRATH DENNIS M · CIK 0001269340 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 F1 · shares: Represents restricted stock units granted on September 19, 2025. The shares underlying the restricted stock units will vest in full on the third anniversary of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date. Read SEC document |
| September 11, 2025 Filed Sep 15, 2025 20:06 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-090002 · tm2526001-5_4seq1.xml · nonDerivative · entry 1 MCGRATH DENNIS M · CIK 0001269340 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,737 F1 · date: The restricted share award shall vest on the last day of the second-year anniversary after the grant date. F2 · balance_after: The number of shares beneficially owned reflects the 20-for-1 reverse stock split effected on August 28, 2025. Read SEC document |
| February 20, 2025 Filed Feb 21, 2025 22:03 UTC | Lucid Diagnostics Inc. LUCD · Entity 6375 | GrantCommon stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-003171 · form4.xml · nonDerivative · entry 1 MCGRATH DENNIS M · CIK 0001269340 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,343,569 F1 · shares: Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2028. Such restricted stock is subject to forfeiture if the requisite service period is not completed. F2 · balance_after: Includes 19,169 shares of Lucid common stock distributed by PAVmed on February 15, 2024 to Mr. McGrath, representing his share of the shares of Lucid common stock distributed by PAVmed to its shareholders on a pro rata basis on such date. Read SEC document |
| December 12, 2024 Filed Dec 16, 2024 21:06 UTC | CITIUS ONCOLOGY, INC. CTOR · Entity 6935 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0001213900-24-109298 · ownership.xml · derivative · entry 1 MCGRATH DENNIS M · CIK 0001269340 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2034-12-12 F1 · derivative.exercise_date: The options were granted on December 12, 2024. The options will vest 100% on the one-year anniversary of the grant date, provided that the Optionee provides Continuous Service to the Company as of the vesting date Read SEC document |
| November 07, 2024 Filed Nov 12, 2024 22:00 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | GrantStock Option (Right to Purchase Common Stock) · Derivative | 125,000 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001213900-24-096889 · ownership.xml · derivative · entry 1 MCGRATH DENNIS M · CIK 0001269340 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2034-11-07 F1 · derivative.exercise_date: The options were granted on November 7, 2024. The options will vest 100% on the one-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of the vesting date. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 22:26 UTC | CITIUS ONCOLOGY, INC. CTOR · Entity 6935 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0001213900-24-069246 · ownership.xml · derivative · entry 1 MCGRATH DENNIS M · CIK 0001269340 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2033-07-05 F1 · derivative.exercise_date: This option, originally issued by Citius Oncology Sub, Inc., is 100% vested. The option was assumed by Citius Oncology, Inc. in the merger transaction, which closed August 12, 2024. Read SEC document |
| May 07, 2024 Filed May 8, 2024 20:01 UTC | Lucid Diagnostics Inc. LUCD · Entity 6375 | GrantCommon stock | 400,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-009638 · form4.xml · nonDerivative · entry 1 MCGRATH DENNIS M · CIK 0001269340 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,043,569 F1 · shares: Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2026. Such restricted stock is subject to forfeiture if the requisite service period is not completed. F2 · balance_after: Includes 19,169 shares of Lucid common stock distributed by PAVmed on February 15, 2024 to Mr. McGrath, representing his share of the shares of Lucid common stock distributed by PAVmed to its shareholders on a pro rata basis on such date. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 21:18 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock | 80,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-032408 · tm248350-3_4seq1.xml · nonDerivative · entry 1 MCGRATH DENNIS M · CIK 0001269340 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 154,744 F1 · date: The shares vest as follows: (i) 50% vest on the grant date and (ii) 50% vest in two instalments on the last day of each successive annual anniversary over a two year period. Read SEC document |
| October 10, 2023 Filed Oct 12, 2023 20:15 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | GrantOptions to Purchase Common Stock · Derivative | 75,000 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0001013762-23-003529 · ownership.xml · derivative · entry 1 MCGRATH DENNIS M · CIK 0001269340 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2033-10-10 F1 · security: The options were granted on October 10, 2023. The options will vest 100% on the one-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of the vesting date. F1 · derivative.exercise_date: The options were granted on October 10, 2023. The options will vest 100% on the one-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of the vesting date. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 21:06 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | GrantOptions to Purchase Common Stock · Derivative | 75,000 | $0.00 Strike: $1.42 | $0.00 |
DisclosureSEC source: 0001213900-23-009756 · ownership.xml · derivative · entry 1 MCGRATH DENNIS M · CIK 0001269340 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2033-02-07 F1 · security: The options were granted on February 7, 2023. The options will vest 100% on the one-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of the vesting date. F1 · derivative.exercise_date: The options were granted on February 7, 2023. The options will vest 100% on the one-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of the vesting date. Read SEC document |
| December 21, 2022 Filed Dec 23, 2022 21:30 UTC | DarioHealth Corp. DRIO · Entity 7024 | SaleCommon Stock | 9,872 | $3.97 | $39,205.66 |
DisclosureSEC source: 0001104659-22-129915 · tm2233446-1_4seq1.xml · nonDerivative · entry 1 MCGRATH DENNIS M · CIK 0001269340 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,744 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and were effected to pay Federal and State withholding taxes on vested shares. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.90 to $4.12, inclusive. The Reporting Person undertakes to provide to DarioHealth Corp. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2). Read SEC document |
| May 18, 2022 Filed May 20, 2022 21:01 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock | 55,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-063447 · tm2216123-3_4seq1.xml · nonDerivative · entry 1 MCGRATH DENNIS M · CIK 0001269340 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,616 F1 · shares: The shares vest over three years as follows: 33.333% shall vest after 12 months from the grant date, and the remaining shares shall vest in 2 equal instalments every 2 years thereafter. Read SEC document |
| March 28, 2022 Filed Apr 11, 2022 22:25 UTC | PAVmed Inc. PAVM · Entity 7317 | Tax withholdingCommon stock | 199,973 | $1.18 | $235,968.14 |
DisclosureSEC source: 0001062993-22-010064 · form4.xml · nonDerivative · entry 1 MCGRATH DENNIS M · CIK 0001269340 · President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 755,489 F1 · kind: Payment of payroll withholding tax liability using a portion of securities received from the company. F1 · shares: Payment of payroll withholding tax liability using a portion of securities received from the company. F1 · price: Payment of payroll withholding tax liability using a portion of securities received from the company. Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 01:15 UTC | Lucid Diagnostics Inc. LUCD · Entity 6375 | GrantEmployee stock option (right to buy) · Derivative | 50,000 | $0.00 Strike: $3.95 | $0.00 |
DisclosureSEC source: 0001062993-22-005483 · form4.xml · derivative · entry 1 MCGRATH DENNIS M · CIK 0001269340 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common stock · 50,000 shares Expires 2032-02-18 F1 · derivative.exercise_date: The option vests in 12 quarterly installments, with first installment vesting March 31, 2022. Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 01:15 UTC | PAVmed Inc. PAVM · Entity 7317 | GrantEmployee stock option (right to buy) · Derivative | 150,000 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001062993-22-005484 · form4.xml · derivative · entry 1 MCGRATH DENNIS M · CIK 0001269340 · President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common stock · 150,000 shares Expires 2032-02-18 F1 · derivative.exercise_date: The option vests in 12 quarterly installments, with first installment vesting March 31, 2022. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 01:07 UTC | Lucid Diagnostics Inc. LUCD · Entity 6375 | GrantCommon stock | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-000909 · form4.xml · nonDerivative · entry 1 MCGRATH DENNIS M · CIK 0001269340 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 624,400 F1 · shares: Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of January 7, 2025. Such restricted stock is subject to forfeiture if the requisite service period is not completed. Read SEC document |
| May 27, 2021 Filed May 28, 2021 21:33 UTC | DarioHealth Corp. DRIO · Entity 7024 | SaleCommon Stock | 22,014 | $16.72 | $368,038.86 |
DisclosureSEC source: 0001104659-21-074353 · tm2117872d1_4seq1.xml · nonDerivative · entry 2 MCGRATH DENNIS M · CIK 0001269340 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,616 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 6, 2021, and were effected for tax purposes. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.39 to $17.29, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3). Read SEC document |
| May 26, 2021 Filed May 28, 2021 21:33 UTC | DarioHealth Corp. DRIO · Entity 7024 | SaleCommon Stock | 45,773 | $17.11 | $783,143.99 |
DisclosureSEC source: 0001104659-21-074353 · tm2117872d1_4seq1.xml · nonDerivative · entry 1 MCGRATH DENNIS M · CIK 0001269340 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,630 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 6, 2021, and were effected for tax purposes. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.71 to $17.45, inclusive. The Reporting Person undertakes to provide to DarioHealth Corp. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2). Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 23:05 UTC | PAVmed Inc. PAVM · Entity 7317 | GrantCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001094891-21-000178 · edgar.xml · nonDerivative · entry 1 MCGRATH DENNIS M · CIK 0001269340 · President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 955,462 F1 · price: The issuer granted 150,000 shares of restricted stock to the reporting person pursuant to its long term incentive equity plan. F2 · balance_after: Includes an aggregate of 26,462 shares of common stock purchased pursuant to the issuer's employee stock purchase program. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 21:06 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantRestricted Stock Grant | 29,616 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-006285 · tm213677-2_4seq1.xml · nonDerivative · entry 1 MCGRATH DENNIS M · CIK 0001269340 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,403 F1 · date: The shares vest over three years as follows: 8.333% shall vest on March 31, 2021, and the remaining shares vest in 11 equal instalments every 3 months thereafter. Read SEC document |
| January 19, 2021 Filed Mar 31, 2021 20:11 UTC Amendment | DarioHealth Corp. DRIO · Entity 7024 | GrantRestricted Stock Units | 29,616 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-044749 · tm2111379d2_4a.xml · nonDerivative · entry 1 MCGRATH DENNIS M · CIK 0001269340 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,403 F1 · security: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F2 · date: The shares vest over three years as follows: one third of the shares vest on each annual anniversary date of the date of grant; provided, however that the shares shall vest on a pro rata basis on the date the Reporting Person's continuous service to the Issuer ceases. The shares shall immediately vest in the event of a change of control that occurs prior to, or within, 60 days of the termination of the Reporting Person's employment or retention with the Issuer. Read SEC document |
| July 20, 2020 Filed Jul 22, 2020 20:11 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock | 2,378 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-085628 · tm2025176d7_4.xml · nonDerivative · entry 1 MCGRATH DENNIS M · CIK 0001269340 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,787 F1 · shares: The reporting person was awarded such securities in exchange for waiving director fees owed for the second quarter of 2020. Read SEC document |
| April 30, 2020 Filed May 4, 2020 21:23 UTC | PAVmed Inc. PAVM · Entity 7317 | GrantCommon Stock | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001094891-20-000065 · edgar.xml · nonDerivative · entry 1 MCGRATH DENNIS M · CIK 0001269340 · President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 791,704 F1 · price: The issuer granted 250,000 shares of restricted stock to the reporting person pursuant to its long term incentive equity plan. Read SEC document |
| April 03, 2020 Filed Apr 7, 2020 20:07 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock | 2,378 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-044156 · tm2015091d6_4.xml · nonDerivative · entry 1 MCGRATH DENNIS M · CIK 0001269340 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,409 F1 · shares: The reporting person was awarded such securities in exchange for waiving director fees owed for the first quarter of 2020. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 21:15 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-021769 · tm206156d3_4.xml · nonDerivative · entry 1 MCGRATH DENNIS M · CIK 0001269340 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,031 Read SEC document |
| January 28, 2020 Filed Jan 30, 2020 21:07 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock | 2,378 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-008683 · tm206156d2_4.xml · nonDerivative · entry 1 MCGRATH DENNIS M · CIK 0001269340 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,031 F1 · shares: The reporting person was awarded such securities in exchange for waiving director fees owed for the fourth quarter of 2019. Read SEC document |
| December 23, 2019 Filed Dec 26, 2019 21:06 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock | 2,378 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-076119 · tm1927375-3_4.xml · nonDerivative · entry 1 MCGRATH DENNIS M · CIK 0001269340 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,653 F1 · shares: The reporting person was awarded such securities in exchange for waiving director fees owed for the third quarter of 2019 in the aggregate amount of $10,250. Read SEC document |
| July 09, 2019 Filed Jul 10, 2019 20:05 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock | 34,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-034299 · tv524962_4.xml · nonDerivative · entry 1 MCGRATH DENNIS M · CIK 0001269340 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,426 F1 · shares: The reporting person was awarded such securities in exchange for waiving director fees owed for the first and second quarters of 2019 in the aggregate amount of $20,500. Read SEC document |
| May 24, 2019 Filed May 28, 2019 20:06 UTC | PAVmed Inc. PAVM · Entity 7317 | PurchaseCommon Stock | 5,000 | $1.09 | $5,428.50 |
DisclosureSEC source: 0001094891-19-000123 · edgar.xml · nonDerivative · entry 1 MCGRATH DENNIS M · CIK 0001269340 · President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 529,000 Read SEC document |
| April 29, 2019 Filed Apr 30, 2019 21:01 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock | 32,974 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-022460 · tv520231_4.xml · nonDerivative · entry 1 MCGRATH DENNIS M · CIK 0001269340 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,260 Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 21:10 UTC | PAVmed Inc. PAVM · Entity 7317 | GrantCommon Stock | 500,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001094891-19-000092 · edgar.xml · nonDerivative · entry 1 MCGRATH DENNIS M · CIK 0001269340 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 524,000 F1 · price: The issuer granted 500,000 shares of restricted stock to the reporting person pursuant to its long term incentive equity plan. Read SEC document |
| January 27, 2019 Filed Jan 29, 2019 21:03 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock | 10,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-003511 · tv511865_4.xml · nonDerivative · entry 1 MCGRATH DENNIS M · CIK 0001269340 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,286 F1 · shares: The reporting person was awarded such securities in exchange for waiving director fees owed for the fourth quarter of 2018 in the amount of $10,250. Read SEC document |
| October 03, 2018 Filed Oct 5, 2018 20:23 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock | 10,312 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-052756 · tv504220_4.xml · nonDerivative · entry 1 MCGRATH DENNIS M · CIK 0001269340 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,036 F1 · shares: The reporting person was awarded such securities in exchange for waiving director fees owed for the third quarter of 2018 in the amount of $10,250. Read SEC document |
| July 09, 2018 Filed Jul 10, 2018 20:07 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock | 7,039 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-037842 · tv498261_form4.xml · nonDerivative · entry 1 MCGRATH DENNIS M · CIK 0001269340 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,724 F1 · shares: The reporting person was awarded such securities in exchange for waiving director fees owed for the second quarter of 2018 in the amount of $10,250. Read SEC document |
| June 12, 2018 Filed Feb 4, 2019 22:04 UTC | PAVmed Inc. PAVM · Entity 7317 | OtherSubscription Rights (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $1.15 | $0.00 |
DisclosureSEC source: 0001094891-19-000046 · edgar.xml · derivative · entry 3 MCGRATH DENNIS M · CIK 0001269340 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Units (1 share of Common Stock and 1 Series Z Warrant) · 12,000 shares Expires 2018-06-12 Read SEC document |
| June 12, 2018 Filed Feb 4, 2019 22:04 UTC | PAVmed Inc. PAVM · Entity 7317 | OtherSeries Z Warrants · Derivative | 12,000 | Not disclosed Strike: $1.60 | Not disclosed |
DisclosureSEC source: 0001094891-19-000046 · edgar.xml · derivative · entry 2 MCGRATH DENNIS M · CIK 0001269340 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2024-04-30 F1 · price: The reporting person purchased units from the issuer in the issuer's equity rights offering, each unit consisting of one share of the issuer's common stock and one Series Z Warrant, at a price of $1.15 per unit. Read SEC document |
| June 12, 2018 Filed Feb 4, 2019 22:04 UTC | PAVmed Inc. PAVM · Entity 7317 | OtherCommon Stock | 12,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001094891-19-000046 · edgar.xml · nonDerivative · entry 1 MCGRATH DENNIS M · CIK 0001269340 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 F1 · price: The reporting person purchased units from the issuer in the issuer's equity rights offering, each unit consisting of one share of the issuer's common stock and one Series Z Warrant, at a price of $1.15 per unit. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 20:07 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock | 24,353 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-033544 · tv496162_4.xml · nonDerivative · entry 1 MCGRATH DENNIS M · CIK 0001269340 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,685 Read SEC document |
| April 23, 2018 Filed Apr 25, 2018 20:10 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock | 6,653 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-022379 · tv491867_4.xml · nonDerivative · entry 1 MCGRATH DENNIS M · CIK 0001269340 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,332 F1 · shares: The reporting person was awarded such securities in exchange for waiving director fees owed for the first quarter of 2018 in the amount of $10,250. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 21:25 UTC | PAVmed Inc. PAVM · Entity 7317 | GrantEmployee Stock Option (Right to Buy) · Derivative | 195,108 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001094891-18-000047 · edgar.xml · derivative · entry 1 MCGRATH DENNIS M · CIK 0001269340 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,108 Underlying: Common Stock · 195,108 shares Expires 2028-02-14 F1 · derivative.exercise_date: The option vests in 12 equal quarterly installments commencing on March 31, 2018. Read SEC document |
| January 04, 2018 Filed Jan 8, 2018 21:17 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock | 6,531 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-001308 · tv482698_4.xml · nonDerivative · entry 1 MCGRATH DENNIS M · CIK 0001269340 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,679 F1 · shares: The reporting person was awarded such securities in exchange for waiving director fees owed for the fourth quarter of 2017 in the amount of $10,250. Read SEC document |
| December 22, 2017 Filed Dec 27, 2017 17:21 UTC | FC Global Realty Inc FCRE · Entity 169560 | OtherFC Global Common Stock | 977,960 | $1.00 | $977,666.61 |
DisclosureSEC source: 0001615774-17-007639 · s108552_form4.xml · nonDerivative · entry 1 MCGRATH DENNIS M · CIK 0001269340 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,029,238 F1 · security: The transactions reported on this Form 4 were effected pursuant to a Convertible Payout Note dated May 17, 2017 and the Stock Grant Agreement dated December 22, 2017. F1 · shares: The transactions reported on this Form 4 were effected pursuant to a Convertible Payout Note dated May 17, 2017 and the Stock Grant Agreement dated December 22, 2017. F2 · price: The price reported in Column 4 was set by the terms of the Convertible Payout Note dated May 17, 2017 and the Stock Grant Agreement dated December 22, 2017. F3 · balance_after: The total shares reflected in Column 5 includes the shares granted under the Convertible Payout Note dated May 17, 2017 and the Stock Grant Agreement dated December 22, 2017 as well as the shares previously held by Mr. McGrath after adjustment for a 1-for-5 reverse stock split in September 2016. Read SEC document |
| December 22, 2017 Filed Dec 28, 2017 15:30 UTC Amendment | FC Global Realty Inc FCRE · Entity 169560 | OtherFC Global Common Stock | 977,960 | $1.00 | $977,666.61 |
DisclosureSEC source: 0001615774-17-007652 · s108570_form4a.xml · nonDerivative · entry 1 MCGRATH DENNIS M · CIK 0001269340 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,029,238 F1 · security: The transactions reported on this Form 4 were effected pursuant to a Convertible Payout Note dated May 17, 2017 and the Stock Grant Agreement dated December 22, 2017. F1 · shares: The transactions reported on this Form 4 were effected pursuant to a Convertible Payout Note dated May 17, 2017 and the Stock Grant Agreement dated December 22, 2017. F2 · price: The price reported in Column 4 was set by the terms of the Convertible Payout Note dated May 17, 2017 and the Stock Grant Agreement dated December 22, 2017. F3 · balance_after: The total shares reflected in Column 5 includes the shares granted under the Convertible Payout Note dated May 17, 2017 and the Stock Grant Agreement dated December 22, 2017 as well as the shares previously held by Mr. McGrath after adjustment for a 1-for-5 reverse stock split in September 2016. Read SEC document |
| October 23, 2017 Filed Oct 25, 2017 20:06 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock | 5,521 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-054095 · tv477607_4.xml · nonDerivative · entry 1 MCGRATH DENNIS M · CIK 0001269340 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,148 F1 · shares: The reporting person was awarded such securities in exchange for waiving director fees owed for the third quarter of 2017 in the amount of $10,250. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.